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Summary
 
Cholera toxin (CT) is a potent mucosal vaccine adjuvant, which has been shown to induce T
helper cell type 2 (Th2) responses in systemic and mucosal tissues. We report that CT inhibits
the production of interleukin (IL)-12, a major Th2 counterregulatory cytokine. IL-12 p70 pro-
duction by stimulated human monocytes was inhibited by CT in a dose-dependent manner.
This suppression occurred at the level of gene transcription, was maximal at low concentrations
of CT, and was dependent on the A subunit of the toxin, since purified CT B subunit had
minimal effect. CT also inhibited the production of IL-12 p70 by monocyte-derived dendritic
cells, as well as the production of tumor necrosis factor 
 
a
 
, but not IL-10, IL-6, or transforming
growth factor (TGF)-
 
b
 
1
 
, by stimulated monocytes. The effects of CT were not due to auto-
crine production of IL-10, TGF-
 
b
 
1
 
, or prostaglandin E
 
2
 
. CT inhibited the production of IFN-
 
g
 
by anti-CD3-stimulated human peripheral blood mononuclear cell, due in part to suppression
of IL-12 production, but also to the inhibition of expression of the 
 
b
 
1 and 
 
b
 
2 chains of the IL-12
receptor on T cells. In vivo,
 
 
 
mice given CT before systemic challenge with lipopolysaccharide
had markedly reduced serum levels of IL-12 p40 and interferon 
 
g
 
. These data demonstrate two
novel mechanisms by which CT can inhibit Th1 immune responses, and help explain the abil-
ity of mucosally administered CT to enhance Th2-dependent immune responses.
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I
 
mmunization at mucosal surfaces can result in the induc-
tion of a broad range of immune responses. The applica-
tion of soluble protein antigens applied to the nasal or in-
testinal mucosa in the absence of adjuvants normally results
in systemic tolerance due either to clonal T cell anergy and
deletion, or to the induction of antigen-specific T cells that
secrete suppressive cytokines such as TGF-
 
b
 
1
 
 and IL-10
(for review see references 1, 2). B cell responses are also
suppressed primarily due to a lack of T cell help (3, 4). In
animal studies, oral (mucosal) tolerance has been deter-
mined either (a) by demonstrating suppressed delayed-type
hypersensitivity (DTH)
 
1
 
 reactions, reduced systemic anti-
body responses, and inhibited in vitro
 
 
 
T cell proliferation
and cytokine production after antigen feeding and subse-
quent systemic antigenic challenge in complete Freund’s
adjuvant, or (b) by resistance to the induction of autoim-
mune diseases, such as experimental autoimmune encepha-
lomyelitis, in animals fed self-antigens. In contrast to the
induction of tolerance, the mucosal administration of pro-
tein antigens together with adjuvants, such as those nor-
mally expressed by infecting microbes, vaccine vectors, or
in the form of ADP-ribosylating bacterial toxins such as
cholera toxin (CT), results in the abrogation of oral toler-
ance, the induction of both local secretory IgA (sIgA) and
systemic (IgG) humoral immunity, and the induction of
cytotoxic T cell responses (for review see references 5–7).
The ability of CT to prevent oral tolerance and induce
strong systemic immune responses to mucosal antigens is
shared by the genetically and structurally similar heat-labile
toxin (LT) from 
 
Escherichia coli
 
 (8). These bacterial toxins
are composed of a monomeric “A” and a pentameric “B”
subunit. The B subunit binds to cell surface gangliosides
and facilitates entry of the A subunit into the cell. Once in-
side the cell, the A subunit acts to catalyze the ADP-ribosy-
lation of the intracellular G protein G
 
s
 
a
 
. Subsequently, the
covalently modified G
 
s
 
a
 
 dissociates from the G
 
s
 
bg
 
 dimer and
 
1
 
Abbreviations used in this paper:
 
 CT, cholera toxin; DTH, delayed type hy-
persensitivity; LT, heat-labile toxin; SAC, 
 
Staphylococcus aureus
 
, Cowan’s
strain I; sIgA, secretory immunoglobulin A. 
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activates adenylate cyclase, causing an increase in intracellu-
lar cAMP. During human infection with 
 
Vibrio cholera
 
, or
enterotoxigenic 
 
E
 
.
 
 coli
 
, the induction of cAMP in intestinal
epithelial cells by CT or LT results in active fluid secretion
and diarrhea.
The mechanisms by which CT or LT act as mucosal ad-
juvants, including the extent to which this adjuvanticity re-
lies on their ability to induce cAMP, are not fully under-
stood, primarily because these toxins have broad effects on
both immune and nonimmune cells (5–7). Some of the re-
ported effects of CT that have potential relevance to its
adjuvanticity are the ability to enhance antigen transport
across the epithelium (9), the production of IL-6 and IL-1
from epithelial cells (10, 11), the expression of T cell co-
stimulatory molecules, such as B7-2 (CD86) (12), by
APCs, and the promotion of B cell differentiation (13, 14).
In vivo, CT has also been shown to augment T cell acti-
vation and differentiation. In this regard, several studies
of restimulated lymphoid cells, isolated from mice mucos-
ally immunized with CT as an adjuvant, have demonstrated
a Th2-dominant T cell response with increased production
of IL-4, IL-5, and IL-10 (15–18). Consistent with this find-
ing, mucosal (17–21), as well as systemic (16) immuni-
zation with a protein and CT results in serum levels of
antigen-specific IgG1 that are consistently higher (10–
100-fold) than the levels of IgG2a; in several studies, high
levels of IgG1 and no IgG2a were found (16, 17, 22). In
addition, oral immunization with CT can induce the pro-
duction of IL-4–dependent antigen-specific IgE (16–18,
20, 23), which can result in IgE-mediated anaphylaxis on
secondary antigenic challenge (17, 20). Th2 responses are
also important for the optimal induction of sIgA (21, 24);
therefore, it is logical that CT-driven Th2 responses are
important for the ability of CT to induce mucosal humoral
immunity to a coadministered oral antigen. Consistent
with this possibility is the fact that IL-4
 
2/2
 
 mice are resist-
ent to the adjuvant effects of CT, including the induction
of IgA at mucosal surfaces (17, 21).
Currently it is not clear why immunization with CT re-
sults in a Th2-dominated T cell response. To explore this
issue, we initially determined whether CT could inhibit
the production of IL-12, a major counterregulatory cyto-
kine for the induction of Th2 T cell responses (for review
see references 25, 26). This possibility was suggested by
studies demonstrating that administration of exogenous IL-12
redirects Th2 to Th1 responses after oral immunization
with CT (18). We found that CT, as well as the related LT,
but not purified CT B subunit (CT-B), inhibited IL-12
p70 production by both human monocytes and human
monocyte-derived dendritic cells (DCs) in response to a
variety of stimuli. This suppression by CT was dose depen-
dent, probably acted at the level of gene transcription, and
was selective. We next determined whether CT could sup-
press the responsiveness of lymphocytes to IL-12. We
found that CT could inhibit the expression of the 
 
b
 
1 and
 
b
 
2 chains of IL-12R on human T cells stimulated in vitro
with anti-CD3. Finally, we demonstrated the relevance of
these effects by showing that CT can inhibit IFN-
 
g
 
 pro-
duction both in vitro, in cultures of human PBMCs, and in
vivo, in mice challenged systemically with LPS.
 
Materials and Methods
 
Reagents.
 
CT and purified CT-B were purchased from List
Biological Laboratories. 
 
E. coli
 
 LT, LPS (
 
E. coli
 
 serotype O127:
B8), and indomethacin were obtained from Sigma Chemical Co.
 
Staphylococcus aureus
 
, Cowan’s strain I (SAC), was supplied by
Calbiochem. Recombinant human IFN-
 
g
 
, IL-4, and GM-CSF
were purchased from Genzyme Diagnostics. Recombinant hu-
man IL-12, neutralizing antibody to human TGF-
 
b
 
1
 
 (polyclonal
chicken Ig) and control antibody (normal chicken Ig), neutraliz-
ing antibody to human IL-10 (clone 23738.11), and isotype con-
trol (clone 20116.11), as well as neutralizing antibody to human
IL-12 (polyclonal goat IgG), were obtained from R&D Systems.
Recombinant trimerized human CD40L (CD154) was provided
by Immunex Corp.
 
Isolation and Stimulation of Human Monocytes and Dendritic
Cells.
 
Human monocytes were obtained from normal healthy
donors (total
 
 n 
 
5 
 
25) by standard leukaphoresis, purified by
counterflow centrifugation (elutriation), which yielded cells of
uniform forward/side scatter that were 95–99% CD14
 
1
 
 by flow
cytometry. Cells were cultured at a density of 2 
 
3 
 
10
 
6
 
 cells/ml in
1 ml of RPMI 1640 (Biofluids Inc.) supplemented with 10% FCS
(Biofluids Inc.), 100 
 
m
 
g/ml penicillin, 100 
 
m
 
g/ml streptomycin,
50 
 
m
 
g/ml gentamicin, 5% NCTC-109 media (Biofluids Inc.),
15 mM Hepes, and 200 mM glutamine (cRPMI) at 37
 
8
 
C and 6%
CO
 
2
 
 unless otherwise noted. For measurement of cytokine pro-
duction, human monocytes were preincubated with media alone
or with varying concentrations of CT, CT-B, or LT, for 1 h at
37
 
8
 
C before stimulation with SAC (0.01% wt/vol) and IFN-
 
g
 
(100 ng/ml), LPS (1 
 
m
 
g/ml) and IFN-
 
g
 
 (100 ng/ml), or CD40L
(3 
 
m
 
g/ml) and IFN-
 
g
 
 (100 ng/ml) for 24 h, after which culture
supernatants were collected and stored at 
 
2
 
20
 
8
 
C until assayed for
cytokines.
Dendritic cells were derived from elutriated monocytes as pre-
viously described (27). In brief, monocytes were cultured for 7 d
in cRPMI supplemented every other day with IL-4 (100 ng/ml)
and GM-CSF (100 ng/ml). Nonadherent cells were harvested by
gentle washing, and the majority (70–90%) were demonstrated
by flow cytometry to express high levels of CD1a (PharMingen)
and low levels of CD83 (PharMingen; data not shown), consis-
tent with prior reports (27). Greater than 95% of the cells ex-
cluded trypan blue, and demonstrated characteristic dendrite for-
mation on examination with phase-contrast, light microscopy.
The 
 
DCs
 
 were resuspended at a density of 10
 
6
 
 cells/ml in
cRPMI, and treated with CT (10 ng/ml), CT-B (10 ng/ml), or
media alone for 1 h before stimulation with either SAC (0.01%)
and IFN-
 
g
 
 (100 ng/ml), or CD40L (3 
 
m
 
g/ml) and IFN-
 
g
 
 (100
ng/ml). Supernatants were collected after 24 h of culture and
stored at 
 
2
 
20
 
8
 
C until assayed for cytokines.
To determine the role of autocrine inhibitors of IL-12 in the
monocyte cultures, elutriated monocytes were preincubated for 1 h
with CT (10 ng/ml) or media alone and one of the following:
neutralizing antibody to TGF-
 
b
 
1
 
 (10 
 
m
 
g/ml) or control antibody
(10 
 
m
 
g/ml), neutralizing antibody to IL-10 (2.5 
 
m
 
g/ml) or iso-
type matched control antibody (2.5 
 
m
 
g/ml), or indomethacin
(10
 
2
 
5
 
 M). SAC (0.01%) and IFN-
 
g
 
 (100 ng/ml) were then
added, and after 24 h of culture, supernatants were harvested and
stored at 
 
2
 
20
 
8
 
C until assayed for IL-12 p70 production.
 
Cytokine ELISAs.
 
Cell culture supernatants were assayed for
cytokines by ELISA using matched antibody pairs according to 
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the manufacturer’s suggestions. ELISA reagents for human IL-12
p70 were purchased from R&D Systems, and for IL-10, TNF-
 
a
 
,
and IFN-
 
g
 
 from Biosource International; the respective capture
and detection antibodies were as follows: IL-12 p70 clone
24945.11 and polyclonal goat IgG, IL-10 clones AHC8102 and
AHC7109, TNF-
 
a
 
 clones AHC3712 and AHC3419, and IFN-
 
g
 
clones AHC4432 and AHC4539. In brief, the capture antibody
was bound to 96-well ELISA plates (Immulon 4™; Dynex) in
the appropriate buffer overnight at 4
 
8
 
C; capture antibody for
IL-12 p70 was used at a concentration of 4 
 
m
 
g/ml diluted in
PBS; IL-10, TNF-
 
a
 
, and IFN-
 
g
 
 capture antibodies were used in a
concentration of 2 
 
m
 
g/ml diluted in bicarbonate buffer (pH 9.6).
The plates were then washed (three times) with PBS with 0.05%
Tween 20, and blocked for 2 h at room temperature; 1% BSA,
5% sucrose, and 0.05% sodium azide in PBS (pH 7.3) was used to
block the IL-12 p70 plates, and 3% BSA in PBS was used for the
remaining cytokines. Cytokine standards and supernatants were
diluted as necessary; 20 mM Tris-HCl, 150 mM NaCl, 0.05%
Tween 20, and 0.1% BSA was used as the diluent for the IL-12
p70 assay, the IL-10, TNF-
 
a
 
, and IFN-
 
g
 
 ELISAs used 3% BSA
in PBS as a diluent. The ELISA plates were then incubated over-
night at 4
 
8
 
C. The plates were washed, and bound cytokine was
revealed with a biotin-labeled detecting antibody (2 h at room
temperature). IL-12 p70 detection antibody was diluted 1:333,
whereas IL-10, TNF-
 
a
 
, and IFN-
 
g
 
 detection antibodies were di-
luted 1:1,000. This was followed by horseradish peroxidase–con-
jugated streptavidin (Zymed; 1:1,000 for 30 min at room temper-
ature), and the substrate 
 
o
 
-phenylenediamine dihydrochloride
(OPD; Sigma Chemical Co.) at 0.5 mg/ml in phosphate-citrate
buffer (pH 5.0) and 0.03% H
 
2
 
O
 
2
 
. Optical density of the individ-
ual wells was determined at 450 nm using an automated ELISA
reader (Dynex). The lower limit of sensitivity of the assays was 32
pg/ml for IL-12 p70, IL-10, and IFN-
 
g
 
, and 64 pg/ml for TNF-
 
a
 
.
Assays for IL-6 and TGF-
 
b
 
1
 
 were performed using ELISA kits
from R&D systems and Genzyme Diagnostics, respectively, ac-
cording to the manufacturers’ instructions. TGF-
 
b
 
1
 
 levels were
measured after acidification, and therefore reflect both the active
and latent forms of TGF-
 
b
 
1
 
.
 
Reverse Transcriptase PCR.
 
Total RNA was obtained from
10
 
7
 
 elutriated monocytes using STAT-60 (TEL-TEST Inc.) ac-
cording to the manufacturer’s instructions. RNA concentrations
were determined by measuring the optical density at 260 nm.
mRNA for each experimental condition was reverse transcribed
with oligo (dT) priming to first strand cDNA using Superscript
II™ reverse transcriptase (GIBCO BRL). In brief, 1 
 
m
 
g of total
RNA suspended in RNAse free water was added to 16 
 
m
 
l of a
reverse transcription reaction mixture consisting of 20 mM Tris-
HCL, 2.5 mM MgCl
 
2
 
, 50 mM KCl, 10 mM dithiothreitol, and
1 mM dNTP. After an initial incubation for 5 min at 42
 
8
 
C, 200 U
of Superscript II™ reverse transcriptase was added and the reac-
tion was continued for 50 min at 42
 
8
 
C, and then terminated at
70
 
8
 
C for 10 min. The samples were then chilled on ice for 15
min. RNAse H (2 U) was then added, and the was reaction incu-
bated for 20 min at 37
 
8
 
C. The first strand cDNA was then stored
at 
 
2
 
80
 
8
 
C before PCR amplification.
PCR amplification was performed using 2 
 
m
 
l of cDNA template,
and 50 
 
m
 
l of a reaction mixture consisting of 20 mM Tris-HCl, 50
mM KCl, 0.2 mM dNTP, 1.25 mM MgCl
 
2
 
, and 2.5 U Platinum
 
Taq™ DNA polymerase (GIBCO BRL). The following primer
pairs were used at a concentration of 1 mM: IL-6, sense 59-ATG-
AACTCCTTCTCCACAAGCGC-39, antisense 59-GAAGAGCC-
CTCAGGCTGGACTG-39; IL-12 p40, sense 59-AGAGGCT-
CTTCTGACCCCCAG-39, antisense 59-CTCTTGCTCTTGCC-
CTGGACCTG-39; IL-12 p35, sense 59-TCAGCAACATGCTC-
CAGAAGGC-39, antisense 59-TGCATTCATGGTCTTGAAC-
TCCACC-39; and GAPDH, sense 59-TGAAGGTCGGAGT-
CAACGGATTTGGT-39, antisense 59-CATGTGGGCCATG-
AGGTCCACCAC-39. PCR amplification was performed under
the following conditions: initial denaturation at 948C for 2 min,
followed by cycles of 948C for 45 s, 608C for 60 s, and 708C for
90 s, and a final elongation step of 708C for 5 min. The number
of amplification cycles was determined by prior experiments to
ensure linear phase amplification of cDNA template (data not
shown). GAPDH was amplified 25 cycles, IL-6 and IL-12 p40 30
cycles, and IL-12 p35 32 cycles. Amplified PCR products were
resolved by gel electrophoresis on a 1.5% agarose gel, and stained
with ethidium bromide.
Isolation and Stimulation of Human PBMCs. PBMCs were ob-
tained from three healthy donors by centrifugation of whole
blood of over Ficoll-sodium diatrizoate (LSM® Lymphocyte Sep-
aration Medium; Organon Teknika Corp.) using the recom-
mended standard procedures (28). Cells were extensively washed
and cultured at a density of 106 cells/ml cRPMI in the presence or
absence of CT (10 ng/ml) for 1 h. The PBMCs were then stimu-
lated with nothing (controls), soluble anti-CD3 alone (1 mg/ml),
rIL-12 alone (1 ng/ml), anti-CD3 and anti-IL-12 (1 mg/ml), or
anti-CD3 and rIL-12. After 72 h, cell supernatants were har-
vested and stored at 2208C until assayed for cytokines. For cell
proliferation studies, identical conditions were used; however,
cells were plated in triplicate in 96-well U-bottomed microtiter
plates with a total cell culture volume of 100 ml/well. After 72 h
in culture, the plates were pulsed for 6 h with [3H]thymidine (1
mCi/well) and frozen overnight at 2208C. The plates were
thawed, and 3H-incorporation from cell lysates was determined
using a Betaplate™ cell harvester and liquid scintillation counter
(Wallac Inc.).
Flow Cytometry for IL-12Rb1 and IL-12Rb2 Chain Expression.
PBMCs were obtained as above from two healthy donors on
two separate occasions and cultured at a density of 106 cells/ml
cRPMI in the presence or absence of CT (10 ng/ml) for 1 h,
and then stimulated with soluble anti-CD3 (1 mg/ml). Controls
were cultured without stimulation. The cells were harvested after
72 h of culture. 106 cells in 100 ml staining buffer (PBS contain-
ing 0.2% BSA and 0.1% sodium azide) were sequentially incu-
bated with rat anti–human mAb for the IL-12Rb1 chain or IL-
12Rb2 chain (29) (clones 2B10 and LM-5.2B6, respectively,
provided by Dr. David Presky, Hoffmann-La Roche, Nutley,
NJ) for 30 min, followed by biotinylated anti–rat Ig F(ab9)2 frag-
ments (Boehringer Mannheim Corp.) for 30 min, and finally
with PE-labeled streptavidin (PharMingen) for 20 min. All incu-
bations were performed at 48C in staining buffer, and cells were
washed twice with staining buffer between incubations. The
stained cells were analyzed on a FACScan® flow cytometer using
CellQuest® software (Becton Dickinson).
In Vivo Production of IL-12 and IFN-g after Systemic LPS Chal-
lenge. 6–10-wk-old BALB/c mice housed under standard con-
ditions were treated intraperitoneally with 250 ml of PBS alone
or 250 ml of PBS containing 10 mg of CT. 1 h later, 250 mg LPS
in 100 ml PBS, or PBS alone was injected intraperitoneally. 4 h
later the mice were anesthetized and then bled by cardiac punc-
ture. After clotting the blood for 30 min at 378C, serum was iso-
lated by centrifugation. Serum cytokine levels were measured by
ELISA using murine IL-12 p40 (R&D Systems) and IL-12 p70
(Genzyme) ELISA kits according to the manufacturers’ instruc-
tions, and antibody pairs against murine IFN-g (PharMingen) as
described above. Serum samples for measurement of IL-12 p70544 Cholera Toxin–mediated Suppression of IL-12 and the IL-12R
were used neat, for IL-12 p40 were diluted 1:125, and for IFN-g
diluted 1:5. The lower limit of sensitivity of the murine IL-12
p40, IL-12 p70, and IFN-g ELISAs were 2 pg/ml, 50 pg/ml, and
1 U/ml, respectively.
Statistics. Statistical analysis was performed by paired t testing
using SigmaStat™ software (Jandel Corp.).
Results
Inhibition of IL-12 p70 Production from Human Monocytes
and Dendritic Cells. We initially sought to determine
whether CT had direct effects on IL-12 production by pu-
rified human mononuclear cells. For these assays we pre-
treated elutriated monocytes from random healthy donors
with varying concentrations of CT, LT, or CT-B before
stimulation with SAC and IFN-g. As shown in Fig. 1, CT
and LT, but not CT-B, inhibited the production of IL-12
p70 in a dose-dependent fashion. Inhibition was seen with
doses as low as 1 ng/ml, and were maximal (97% reduction)
at 10 ng/ml for both toxins. At high concentrations (.100
ng/ml), CT-B had minimal suppressive effects (,50% re-
duction) that were not statistically significant. As shown in
Fig. 2 A, this inhibition was not dependent on the cell stim-
ulus, as the effects of CT were similar with two other potent
IL-12 stimuli, LPS and IFN-g, and CD40L and IFN-g.
We then determined whether this inhibitory effect was
also seen with DCs. DCs have been shown to migrate to T
cell regions of lymphoid tissues and present antigen to na-
ive T cells more efficiently than monocyte/macrophages,
and thus are more likely to play a role in directing initial T
cell differentiation (for review see references 30, 31). For
these assays, we established DC populations in vitro from
elutriated human monocytes cultured for 7 d with GM-CSF
and IL-4. These cells were shown to be typical of DCs in
an intermediate stage of differentiation (27), as they had
moderate but consistent dendrite formation by phase-con-
trast light microscopy, and expressed both high levels of
CD1a and low levels of CD83 by flow cytometry (data not
shown). As shown in Fig. 2 B, stimulation of this popula-
tion with CD40L and IFN-g or SAC and IFN-g resulted
in dramatic production of IL-12 p70 (.3,500 pg/ml). Al-
though this was inhibited by .90% with CT (10 ng/ml)
pretreatment, CT-B (10 ng/ml) had minimal inhibitory ef-
fects (,10% suppression) on IL-12 p70 production from
DCs (data not shown).
Inhibition of IL-12 Production by Monocytes Is Selective and
Not Due to Cell Death. We next determined whether the
suppression of cytokine production from monocytes by CT
Figure 1. (A) CT and E. coli LT, but not CT-B, suppressed IL-12 p70
production in a dose-dependent manner. Elutriated human monocytes
(2 3 106 cells/ml) were pretreated with varying concentrations of toxin
for 1 h, followed by stimulation with SAC (0.01%) and IFN-g (100 ng/ml).
24 h after stimulation, cell supernatants were harvested and analyzed by
ELISA for IL-12 p70. Data are mean values 6 SD from three donors per
experimental condition. *P , 0.05 for given concentration, and all higher
concentrations.
Figure 2. (A) Suppression of
IL-12 p70 by CT was independent
of stimuli. Human monocytes (2 3
106 cells/ml) were pretreated for 1 h
with CT (10 ng/ml), and then stim-
ulated with SAC (0.01%), LPS (10
ng/ml), or CD40L (3 mg/ml) and
IFN-g (100 ng/ml). Values are
mean  6  SD from three donors per
experimental condition. (B) CT
markedly suppressed IL-12 p70 pro-
duction in human DCs. DCs were
derived from human monocytes
cultured for 1 wk with IL-4 and
GM-CSF. After phenotypic confirma-
tion, cells (106 cells/ml) were treated
with either SAC (0.01%) and IFN-g
(100 ng/ml) or CD40L (3 mg/ml)
and IFN-g (100 ng/ml) with or
without CT (10 ng/ml) pretreat-
ment. Data are mean values 6 SD of
four separate experiments using DCs
derived from four different donors.
IL-12 production was analyzed by
ELISA.  **P  ,  0.01;  *P , 0.05.545 Braun et al.
was selective for IL-12 p70. As shown in Fig. 3, we found
that, similar to other known inhibitors of IL-12 (32–38), pro-
duction of IL-10, TGF-b1, and IL-6 were not significantly
affected by CT. However, TNF-a was also suppressed (by
90%) by treatment with CT. The suppression of TNF-a by
CT is distinct from that seen with other inhibitors of IL-12,
which typically do not affect TNF-a synthesis (34–38). Al-
though the selective suppression of IL-12 and TNF-a by CT
suggested that this inhibition was not due to cell death, we
confirmed this by determining cell viability at the end of the
24-h culture period. We found that the percentage of cells
excluding trypan blue by visualization with light microscopy
correlated well with the percentage that stained minimally
with propidium iodide as detected with flow cytometry. In
both control cultures and cultures pretreated with either CT
or LT at concentrations of ,1 mg/ml, 70–80% of all mono-
cytes were viable at 24 h. In addition, the total numbers of
cells collected at 24 h from the cultures with and without CT
were similar, suggesting that in vitro cells were not dying in
the presence of CT. CT concentrations .1 mg/ml resulted
in enhanced cell death (data not shown).
Inhibition of IL-12 Production Is Not Due to Known Auto-
crine Inhibitors. To determine whether the inhibition of
IL-12 p70 production could be due to the induction of
several known autocrine IL-12 inhibitors, we pretreated
monocytes with indomethacin (to block the production
of prostaglandins, specifically PGE2), anti-IL-10, or anti-
TGF-b1, together with CT before stimulation with SAC
and IFN-g. As shown in Fig. 4, the inhibition of IL-12 by
CT (10 ng/ml) was not reversed by any of these treat-
ments. These data are consistent with the fact that the levels
of IL-10 and TGF-b1 as measured in monocyte cultures
were unaffected by CT (Fig. 3).
CT Inhibits mRNA for IL-12 p35 and p40 Chains. We
next sought to determine the level at which CT mediates
its suppressive effects. For these studies we used semiquanti-
tative reverse transcription PCR to analyze the levels of
IL-12 p35 and p40 mRNA present in monocytes stimulated
with SAC and IFN-g in the presence and absence of CT.
Stimulation of cells with SAC and IFN-g resulted in in-
creased mRNA for both p35 and p40, as well as IL-6 (Fig.
5). Pretreatment of monocytes with CT (10 ng/ml) resulted
in suppression of SAC and IFN-g–stimulated mRNA levels
for IL-12 p35 and p40, but did not affect levels of mRNA
for IL-6. IL-12 p40 and p35 mRNA expression in CT-
B–treated (10 ng/ml) monocytes did not differ from SAC
Figure 3. CT treatment selectively suppressed IL-12 p70 and TNF-a,
but not IL-10, TGF-b1, or IL-6. Human monocytes (2 3 106 cell/ml)
were stimulated with SAC (0.01%) and IFN-g (100 ng/ml) in the pres-
ence or absence of CT (10 ng/ml). Cytokine production was measured
by ELISA 24 h after stimulation. Data are mean values 6 SD of four sep-
arate experiments using four different donors. **P , 0.01.
Figure 4. CT-mediated suppres-
sion of IL-12 p70 was independent
of known autocrine inhibitors of
IL-12. Elutriated human monocytes
(2 3 106 cells/ml) with or without
CT (10 ng/ml) were incubated with
neutralizing antibody to IL-10 (A),
neutralizing antibody to TGF-b1 (B)
indomethacin (C) to inhibit PGE2
production, and then stimulated
with SAC (0.01%) and IFN-g (100
ng/ml). IL-12 p70 production was
measured 24 h later by ELISA. Data
are mean values 6 SD from three
separate experiments using three dif-
ferent donors. **P , 0.01.
Figure 5. Analysis by reverse
transcription PCR demonstrates
significantly reduced levels of
mRNA for IL-12 p40 and p35,
but not IL-6, in CT-treated cells
after stimulation. mRNA was
obtained at intervals from human
monocytes (107 cells) after stim-
ulation with SAC (0.01%) and
IFN-g (100 ng/ml) in the pres-
ence or absence of CT (10 ng/ml).546 Cholera Toxin–mediated Suppression of IL-12 and the IL-12R
and IFN-g–stimulated controls (Fig. 6). Since previous
studies have shown that IL-12 is primarily regulated at the
level of transcription (39, 40), the data presented here sug-
gest that CT is acting to suppress IL-12 p70 production by
preventing transcription of the genes for both chains of
IL-12.
CT Inhibits Proliferation and IFN-g Production by PBMCs
Stimulated with Anti-CD3. To determine the functional
relevance of the effects of CT on IL-12 production, we
initially examined the ability of CT to inhibit IFN-g
production by PBMCs stimulated with soluble anti-CD3.
Under such stimulation conditions, T cells are activated to
express CD40L, which stimulates CD40-dependent pro-
duction of IL-12 by both monocytes and DCs. In turn, IL-
12 drives IFN-g production by circulating NK and T cells,
and augments CD3-mediated proliferation of T cells. As
shown in Fig. 7, PBMCs stimulated with anti-CD3 pro-
duced IFN-g and proliferated in an IL-12 dependent fash-
ion, as anti–IL-12 abrogated this response. The addition of
CT inhibited IFN-g production as well as proliferation;
however, such inhibition was only partially reversed by the
addition of exogenous IL-12 to the cultures. These latter
findings suggested that CT may also inhibit the responsive-
ness of T or NK cells to IL-12. To examine this possibility,
we stimulated PBMCs with anti-CD3 in the presence or
absence of CT. After 72 h in culture, the level of expres-
sion of the two chains of IL-12R on T cells was deter-
mined by flow cytometry. As shown in Fig. 8, expression
of both the b1 and b2 chains of IL-12R were significantly
upregulated by stimulation with anti-CD3, and this en-
hancement was blocked by treatment with CT. Thus, CT
appears to act by at least two distinct mechanisms to sup-
press IFN-g production in cultured PBMCs.
CT Inhibits IFN-g and IL-12 p40 Production in Mice Chal-
lenged Systemically with LPS. Finally, to demonstrate the
inhibitory effect of CT in an established in vivo model of
IL-12 production, we examined the ability of CT to in-
hibit IFN-g and IL-12 p40 in the serum of mice challenged
systemically with LPS (41, 42). IFN-g production in this
model has been shown to depend on IL-12, as anti–IL-12
inhibits this response. For these studies, mice were given
CT (10 mg/mouse) intraperitoneally 1 h before systemic
challenge with 250 mg of LPS. 4 h later, serum levels of
IL-12 p70, IL-12 p40, and IFN-g were determined by
ELISA. IL-12 p70 was found in the serum of control-stim-
ulated mice at or near the levels of detection of our ELISA
(50–100 pg/ml). Therefore, this measurement was not
helpful for determining levels of IL-12 suppression in vivo.
However, as shown in Table I, we found that prior treatment
with CT resulted in an 80% reduction in serum levels of
IL-12 p40. In addition, in vivo production of IFN-g was
completely suppressed by CT pretreatment. Since IFN-g
production in this model has been shown by several groups to
be IL-12 dependent (41–45), these findings strongly suggest
that bioactive IL-12 was suppressed by CT administration.
Discussion
CT is a potent mucosal vaccine adjuvant that can aug-
ment the production of secretory IgA and prevent the in-
duction of oral tolerance to soluble proteins. These adju-
vant effects are likely due in large measure to its ability to
augment T cell activation and differentiation in vivo. In
Figure 6. Analysis by reverse
transcription PCR demonstrates
no significant difference in lev-
els of mRNA for IL-12 p40 and
p35 in CT-B–treated cells after
stimulation. mRNA was ob-
tained at intervals from human
monocytes (107 cells) after stim-
ulation with SAC (0.01%) and
IFN-g (100 ng/ml) in the pres-
ence or absence of CT-B (10
ng/ml).
Figure 7. (A) IFN-g production
by cultured PBMCs was significantly
reduced by CT treatment. PBMCs
(106 cells/ml) were cultured for 72 h
in the presence or absence of CT (10
ng/ml) with nothing (unstimu-
lated), rIL-12 (1 ng/ml), anti-CD3
(1 mg/ml), anti-CD3 and anti-IL-12
(1 mg/ml), or anti-CD3 and rIL-12.
Supernatants were then harvested
and analyzed for IFN-g production
by ELISA. Data are mean values 6
SD from a total of seven donors
from three separate experiments.
**P ,  0.01; *P  ,  0.05. (B) CT
treatment also inhibited anti-CD3-
mediated cell proliferation. PBMCs
were cultured as noted above for 72 h,
then pulsed for 6 h with [3H]thymi-
dine, harvested, and analyzed. Data
are mean values 6 SD of triplicate
samples from three different donors.
*P , 0.05.547 Braun et al.
this regard, studies of cytokines produced after in vitro re-
stimulation of lymphoid cells isolated from mice mucosally
immunized with CT alone, or with CT as an adjuvant,
have generally demonstrated one of two responses: (a) one
clearly dominated by Th2 cytokines, including IL-4, IL-5,
and IL-10 (15–18), or (b) a mixed Th1 and Th2 cytokine
response showing enhanced production of IFN-g as well
IL-4 (15, 46, 47). However, studies of immunoglobulin
isotypes in CT immunized mice are more consistent in
demonstrating that a Th2 response predominates in vivo
(16–23). In this report, we provide two mechanisms for the
ability of CT to drive Th2 cell differentiation after mucosal
immunization. We demonstrate that the production of IL-12,
a major counterregulatory cytokine for the development of
Th2 responses, by human monocytes and DCs is potently
suppressed by CT. In addition, we demonstrate that T cell
responsiveness to IL-12 is also inhibited by CT, and that
this is due to a decreased expression of the b1 and b2
chains of IL-12R. Finally, we demonstrate the ability of
CT to inhibit IL-12 and/or Th1 responses both in vitro, by
anti-CD3-stimulated human PBMCs, and in vivo, in a
mouse model of septic shock.
IL-12 p70 production by human monocytes in response
to a variety of stimuli (SAC, LPS, or CD40L) in combina-
tion with IFN-g was suppressed by CT in a dose depen-
dent manner (Figs. 1 and 2 A). The CT-related LT from E.
coli similarly suppressed IL-12 p70 production by mono-
cytes stimulated with SAC and IFN-g. In contrast, purified
CT-B had only minimal effects on IL-12 p70 production
and only at concentrations 100–1,000-fold higher than
suppressive doses of the holotoxin. These findings indicate
that the A subunit of CT, and probably of LT, is of primary
importance for the ability of these toxins to suppress IL-12
p70 production. In fact, the minimal suppressive activity
seen here with CT-B, although possibly related to direct
effects of CT-B binding, is most likely due to residual ho-
lotoxin in the CT-B preparations. For the effects seen here,
this would require only 0.1% of active holotoxin, a level
consistent with the reported 0.06–2.0% residual enzymatic
activity of the purified CT-B from List Biologicals.
Whether CT and LT actually act to suppress IL-12 via
the induction of cAMP is not clear. This appears to be the
most likely mechanism, as others have shown that direct
stimulation of cAMP pathways with forskolin, or dibu-
tyryl-cAMP, can inhibit IL-12 p35 and p40 gene transcrip-
tion (37). In addition, PGE2 (37) and b-adrenergic agonists
(38) both activate adenylate cyclase and inhibit IL-12 pro-
duction. However, other IL-12 inhibitors, such as iC3b
(via complement receptor 3; references 34, 48), IgG (via
Fc-receptors; reference 48), measles virus (via CD46; refer-
ence 35), TGF-b1, and IL-10, are not thought to suppress
IL-12 via the induction of cAMP. In addition, a mutant
CT with no detectable ADP-ribosylase activity, due to a
point mutation introduced into the A subunit, was recently
shown to have maintained its adjuvant effects as well as the
ability to induce Th2 responses in vivo (16). These find-
ings, together with reports of the induction of non-cAMP
signaling pathways by CT, but not CT-B (49, 50), suggest
that cAMP-independent, A subunit–dependent processes
could be responsible for the suppression of IL-12 seen here.
We attempted to address this issue by determining whether
defined cAMP, or adenylate cyclase, inhibitors would pre-
vent the suppression of IL-12 by CT. Thus far, we found
these agents to be toxic to monocytes at the concentrations
required to suppress cAMP. We are currently testing the
ability of LT-mutants, which have far less ADP-ribosylase
activity than normal LT, to suppress IL-12.
CT also inhibits IL-12 production from DCs stimulated
with CD40L and IFN-g (Fig. 2 B). Similar to our findings
with monocytes, CT-B did not suppress the production of
IL-12 p70 by DCs. Since DCs are the major APCs for the
induction of primary T cell immune responses (31), this
Figure 8. CT reduced cell sur-
face expression of IL-12Rb1 and
IL-12Rb2 chains in anti-CD3-stim-
ulated PBMCs. Flow cytometry was
performed on 106 PBMCs after 72 h
in culture on cells that were unstim-
ulated (basal expression), cells stimu-
lated with anti-CD3 (1 mg/ml), or
cells stimulated with anti-CD3 in
the presence of CT (10 ng/ml). Data
are representative of flow cytometric
analysis of two separate experiments
each with two different donors. On
average, anti-CD3 stimulation increased b1 chain mean fluorescence by 6.5-fold, and b2 fluorescence by 5.1-fold. In the presence of CT, the average
mean fluorescence of the b1 chain increased by only 3.5-fold, and the b2 chain by only 1.9-fold. This difference was statistically significant (P , 0.05).
Table I. Serum Cytokine Concentrations in 6-wk-old BALB/c Mice
Condition IL-12p40 IFN-g
pg/ml U/ml
Unstimulated ,250 ,5
CT ,250 ,5
LPS 15,167 (6 4,018)** 158.3 (6 65.4)*
LPS/CT 3,625 (6 2,080) ,5
Mice were given 10 mg of CT intraperitoneally 1 h before stimulation
with 250 mg of LPS intraperitoneally. Data are representative of two
separate experiments each with 12 mice (3 in each group). Values are
mean 6 SD of serum levels 4 h after stimulation. (**P , 0.01; *P , 0.05).548 Cholera Toxin–mediated Suppression of IL-12 and the IL-12R
finding implies that induction of primary Th1 T cell re-
sponses can be inhibited directly by CT. Thus, CT could
act at two stages of T cell development; it could inhibit
Th1 priming in lymphoid organs that are more dependent
on DC production of IL-12, and it could inhibit secondary
stimulation of Th1 T cells in inflammatory sites, where
they may be more dependent on macrophage production
of IL-12 for their survival and function. The latter point is
illustrated by the fact that the systemic administration of
IL-12 antibodies to mice with ongoing Th1-mediated ex-
perimental inflammatory colitis results in reversal of the in-
flammation (51), due in large part to the induction of local
T cell apoptosis (Fuss, I., and T. Marth, unpublished data).
The inhibition of IL-12 production and responsiveness
are not the only mechanisms by which CT may drive Th2
T cell responses in vivo. Earlier studies have shown that
CT has the capacity to suppress the production of IL-2 and
IL-2 responsiveness in both resting and activated T cells
(52–54). This effect has been confirmed in Th1 T cell
clones (55). In contrast, CT has little effect on the prolifer-
ation of Th2 clones, or on their production of IL-4 (55),
suggesting that CT may promote Th2 T cell development
partially because of its differential direct suppressive effects
on Th1 cells. Whether active holotoxin is required for these
effects on T cells is not completely clear. In several earlier
studies, CT-B was shown to suppress T cell proliferation and
IL-2 production in vitro (at doses ranging from 100 ng/ml to
4 mg/ml) (54–57). An increase in cAMP was not discernible
in cultures with these concentrations of CT-B, suggesting
this suppression is not due to residual holotoxin activity (54).
However, other studies demonstrate that the induction of
cAMP in activated murine CD41 T cells by treatment with
CT, the combination of forskolin and phosphodiesterase in-
hibitors, or by direct stimulation of cAMP pathways with
dibutyryl-cAMP, results in the enhanced production of IL-4
and IL-5, with concurrent suppression of IL-2 production
(58). Regardless of the mechanisms involved, these studies,
together with the results presented here, suggest that CT, by
blocking IL-12 production and responsiveness in the in-
ductive phase of T cell responses, and by suppressing the
production of and responsiveness to IL-2 and IL-12, but not
IL-4 on secondary T cell stimulation, results in the skewing
of T cell responses to the Th2 phenotype.
These combined effects of CT may also explain some of
the disparate findings in the literature with respect to cy-
tokine responses by cells isolated from mice after CT im-
munization. In this regard, several studies showing a mixed
Th1 and Th2 cytokine response were performed with cells
isolated after a single immunization (15, 46, 47). Since it is
now clear that naive T cells require multiple rounds of stimu-
lation in the presence of IL-4 to acquire a stable Th2 pheno-
type (59, 60), it is possible that T cells isolated after only one
immunization in vivo with CT are incompletely polarized to
the Th2 phenotype, despite being induced in an environment
that may have low levels of IL-12, as well as high levels of
IL-4. Stimulation of these cells in vitro with activated APCs
(taken from non-CT-treated mice) that produce high levels
of IL-12 may result in IL-4 as well as IFN-g production. In
contrast, studies showing distinct Th2 responses in vitro after
CT administration have primarily been performed with cells
isolated from animals given multiple in vivo immunizations
(15–17, 19). Under these conditions, the combined effects of
CT noted above would result in a more stable Th2 pheno-
type after each repeated immunization. Since Th2 cells have
been shown to lose expression of the IL-12Rb2 chain (61),
the more polarized Th2 populations isolated after multiple
immunizations with CT as an adjuvant would not produce
significant amounts of IFN-g in vitro despite high levels of
IL-12 produced by stimulating APCs.
However, the ability of CT to suppress IL-12 produc-
tion and drive Th2 development cannot explain the find-
ings by several groups that CT can augment cytotoxic T
cell responses to antigens, including soluble peptides, ap-
plied to mucosal surfaces (62–64). In fact, IL-12 has long
been known to be capable of directly augmenting CD81
CTL responses (25, 65). Consistent with a similar role for
IL-12 after mucosal immunization, it was recently shown
that after intrarectal immunization with a peptide contain-
ing both helper and CTL epitopes of HIV gp120 using CT
as an adjuvant, a CTL response was induced in wild-type
mice, but not in IFN-g2/2 mice, nor in wild-type mice
pretreated with anti–IL-12 antibody (62).
There are at least two possible explanations for these
seemingly inconsistent findings. First, it is possible that the
level of IL-12 required for the induction of CD81 CTL is
less than that required for the induction of CD41 Th1 re-
sponses, and that CT does not suppress IL-12 below the
level required for CTLs. Indeed, we found that CT does
not completely suppress IL-12 p40 production in vivo (Ta-
ble I). Support for the possibility that CD81 CTLs and
CD41 Th1 cells have differential requirements for IL-12 is
the finding that IFN-g producing alloreactive CD81 T
cells are equivalently induced in wild-type and IL-12 p352/2
mice, which still produce IL-12 p40 that can signal CD81
cells (66). In contrast, the induction of IFN-g–producing
CD41 T cells after systemic immunization is substantially
suppressed in IL-12 p352/2 mice (67, 68) that do not re-
spond to IL-12 p40. The ability of CT to augment CTL in-
duction may thus be due to its positive effects on antigen
adsorption (9), antigen presentation (7, 10, 69, 70), and ex-
pression of other costimulatory molecules, such as B7-2
(CD86; reference 12) and IL-1 (11) in the setting of low but
sufficient levels of IL-12. The fact that the administration of
exogenous IL-12 has recently been shown to significantly
enhance CT-induced CTL at mucosal surfaces in response
to immunization with the HIV peptide vaccine discussed
above (Belyakov, I., unpublished data), is also consistent
with this hypothesis. Second, it is possible that CT has di-
rect positive, rather than inhibitory, effects on CD81 T cells
that enhance their differentiation into CTL. However, this
possibility seems less likely given a recent study demonstrat-
ing that CT and CT-B can inhibit CD81 T cell activation
in vitro (55). Future studies will need to address the mecha-
nisms by which CT can drive the induction of CTL.
Also difficult to explain with the current data is the fact LT
given to mice orally induces a mixed Th1 and Th2 response,549 Braun et al.
with significant amounts of antigen-specific IgG2a, whereas
CT induces a Th2 response with strong IgG1 and IgG2b an-
tibody responses (71). One possible explanation is suggested
by our preliminary observation that the potency of LT is less
than that of CT with respect to IL-12 suppression (Fig. 1).
Clearly these experiments will need to be repeated with a va-
riety of toxin preparations to confirm this observation; how-
ever, a partial reduction of IL-12 by LT could potentially ex-
plain why this toxin does not induce T cell responses as
strongly polarized in the Th2 direction as does CT. In addi-
tion, it has been suggested that since LT-B has higher affinity
for galactose residues than has CT-B, it may have higher
binding affinity for a broader range of gangliosides than CT
(e.g., GM2 or asialo-GM1 in addition to GM1), thus affecting
the cell types that are potentially activated by the toxins (6,
72–74). Such a difference could also potentially account for
differences between CT and LT in vivo.
We found that CT also inhibited TNF-a production,
but had no effect on TGF-b1, IL-6, or IL-10 production
by stimulated monocytes (Fig. 3). Although the latter cy-
tokines were not responsible for suppressing the production
of IL-12 via an autocrine inhibitory circuit, they each are
thought to be important for the differentiation of IgA B
cells. TGF-b1 is an essential factor (75), and IL-10 and IL-6,
in addition to IL-4, have additive, significant roles in IgA B
cell switching and differentiation (for a recent review see
reference 76). In fact, IL-10 and IL-6 have been implicated
in the induction of the diminished but present IgA re-
sponses in IL-42/2 mice (22). In addition, both TGF-b1
and IL-10 can act in an autocrine fashion to induce the dif-
ferentiation of naive T cells into cells producing each of
these respective cytokines (77, 78). Thus, in addition to the
direct effects of APC-produced IL-10 and TGF-b1 on B
cells, the uninhibited capacity to produce these cytokines
after treatment with CT could indirectly result in the in-
duction of IL-10– and TGF-b1–producing T cells that
could provide help for IgA B cell responses. Recently, we
also demonstrated in mice that blocking the effect of IL-12
both in vitro and in vivo with anti–IL-12 antibodies results
in enhanced priming for TGF-b1–producing T cells (77,
79, 80), suggesting that the direct inhibition of IL-12 pro-
duction by CT could result in high levels of TGF-b1 pro-
duction that may act in concert with local Th2 cells to drive
high levels of IgA B cell switching and differentiation.
The primary paradox with respect to this reasoning, and
with respect to the action of CT in general, is how CT can
act to promote IgA responses, which are dependent on the
production of TGF-b1, yet result in the abrogation of oral
tolerance (81, 82), a response that can be mediated by T
cells arising in the Peyer’s patches that produce TGF-b1
and IL-10. Unfortunately, this issue has not been ade-
quately addressed, in that all studies of the effect of CT on
oral tolerance have been performed using high dose oral
tolerance regimens that optimally induce T cell anergy and
deletion, rather than with clearly defined low dose regi-
mens that induce regulatory cells (83, 84). The most con-
vincing data has shown that CT can prevent high dose oral
tolerization of antibody responses (23, 82). Although CT
can clearly prevent the deletion of Th2 T cells, studies
showing prevention of tolerance of Th1-mediated re-
sponses, such as DTH, are contradictory (23, 85–87). In
fact, there are clear examples of the ability of CT to pre-
vent oral tolerance with respect to antibody responses,
while concurrently having no effect on “tolerance” of
DTH (85). One could argue that in these studies, the lack
of abrogation of oral tolerance to DTH is actually the lack
of induction of DTH due to deviation to the Th2 pheno-
type (85, 86). Finally, it has been shown that CT can di-
rectly induce B cell differentiation (13) as well as TGF-b1
production from B cells (14), which may drive B cell
switching to IgA. Thus, CT could simultaneously drive T
cells to differentiate into Th2 cells and induce TGF-b1
production from B cells, resulting in IgA production.
The physiologic relevance of the findings presented here
were demonstrated by showing that CT completely inhibited
the production of IFN-g by anti-CD3–stimulated human
PBMCs. This was partially restored by adding IL-12 back to
the cultures (Fig. 7). The fact that IL-12 did not completely
restore IFN-g production in these cultures suggested that CT
also acts to inhibit the responsiveness of T cells to IL-12. In
support of this possibility, we demonstrated by flow cytome-
try that CT also inhibits the anti-CD3–stimulated expression
of the b1 and b2 chains of IL-12R on T cells. It has been
shown that both IL-12R chains are required for high affinity
binding of IL-12 and optimal signal transduction (88, 89).
Finally, the effects of CT were demonstrated in vivo, by
showing that the pretreatment of mice with CT (10 mg/
mouse given intraperitoneally) inhibited both serum IL-12
p40 (80% reduction) and IFN-g (.95% reduction) responses
to systemic challenge with LPS. Since earlier studies have
shown that the induction of serum IFN-g after exposure to
LPS is IL-12 dependent (41–45), these data strongly suggest
that CT inhibited the production of biologically active IL-12
in vivo. In support of this conclusion, an earlier study con-
vincingly demonstrated that the Th2-dominated response af-
ter oral immunization with CT as an adjuvant was reversed
when the mice were also treated with IL-12 (17).
In summary, our data demonstrates that CT can inhibit
Th1 immune responses by its ability to suppress IL-12 pro-
duction from both monocytes and DCs, as well as by its ca-
pacity to inhibit the expression of IL-12 receptors on T
cells. These effects may help to explain the ability of mucos-
ally administered CT to enhance Th2-dependent immune
responses in vivo.
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